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Abstract
Background: Tumor-specific cytotoxic T cells and infiltrating lymphocytes are frequently found
in tumor tissues in patients with nasopharyngeal carcinoma (NPC). Most patients with NPC,
however, especially those with advanced stages, have a poor clinical prognosis despite conventional
immunotherapy. The aim of this work was to examine the effect of indoleamine 2,3-dioxygenase
(IDO), an immunosuppressive enzyme, on the lymphocyte function in NPC.
Methods: T h eN P Cc e l ll i n eC N E 2w a st r e a t e db yi n t e r f e r o n - g (IFNg) and the levels of IDO
expression was analyzed by Western blotting and reverse phase high-performance liquid
chromatography (HPLC). Lymphocytes from health human exposed to the milieu created by
IDO-positive CNE2 cells and the lymphocyte cytotoxicity to target tumor cells was analyzed by
standard lactate dehydrogenase (LDH) release assay. Additionally, expression of IDO was
determined by Immunohistochemical assay in the tumor tissues form clinically evaluated NPC.
Results: IDO expression was acutely induced in the NPC cell line CNE2 by low dose interferon-g
(IFNg) or by co-incubation with activated lymphocytes. Exposure to the milieu created by IDO-
positive CNE2 cells did not promote lymphocyte death, but lymphocyte cytotoxicity against target
tumor cells was impaired. The suppression of lymphocyte cytotoxic function was fully restored
when the conditioned medium was replaced by fresh medium for 24 h. In additionally, the IDO-
positive cells were found scattered in the tumor tissues from patients with NPC.
Conclusion: Altogether, these findings suggest that IDO-mediated immunosuppression may be
involved in the tumor immune evasion, and that blocking IDO activity in tumor cells may help to re-
establish an effective anti-tumor T cell response in NPC.
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Nasopharyngeal carcinoma (NPC) is an Epstein-Barr
virus (EBV)-associated malignancy with high prevalence
in Southern China and Southeast Asia [1]. Guangdong
province, also called Canton, has the highest prevalence,
e a r n i n gN P Ct h en a m eo f‘Canton tumor’.D u et ot h e
non-specific nature of the nasal and aural symptoms and
the difficulty of making a clinical examination of the
nasopharynx, most patients with the disease are diag-
nosed only when the tumor has reached an advanced
stage (stages III and IV) [2]. Radiotherapy is the main
treatment for this disease, but patients with intermediate
and advanced stages who only receive radiotherapy have
a 5-10-year survival rate of only 40%. Hence, novel
approaches to the treatment of NPC are needed to
improve the prognosis of patients with NPC.
Immunotherapeutic strategies aimed at boosting anti-
tumor immunity are promising candidates for the
treatment of NPC. A few studies have focused on
reversing the impaired immune response to NPC tumors
[3]. Determination of the mechanisms behind the
dysfunction of cytotoxic T lymphocytes in patients with
NPC would undoubtedly be of help in the development
of optimal immunotherapeutic strategies for NPC. It has
been reported that cytokine expression in tumor
infiltrating lymphocytes (TILs) in NPC patients is
comparable to that in healthy controls. Interferon-g
(IFNg) is one of the prominent cytokines associated with
immune activation and immunosuppression [4].
IFNg,a l s oc a l l e dt y p eI Ii n t e r f e r o no ri m m u n ei n t e r f e r o n ,
is mainly produced by activated T cells and NK cells, and
acts as an important mediator of the immune system,
involving activities such as immuno-modulation, lym-
phocyte recruitment and activation, anti-pathogen and
anti-tumor activity [5]. Although IFNg was first used to
treat patients with NPC in 1987 [6], there was no further
report on IFNg therapy for NPC since 1993 due to some
cases were shown to be unresponsive. In most cases of
NPC, the dense infiltration of lymphocytes is observed in
the tumor site, and EBV-associated viral antigens in
tumor cells are presented for lymphocyte recognition,
nevertheless IFNg fails to exert its intended anti-viral and
anti-tumor effects in the patients with NPC [7,8].
IFNg has the specific ability to induce indoleamine 2,3-
dioxygenase (IDO) expression in various kinds of
tumors [9]. IDO is responsible for initiating the first,
rate-limiting step in tryptophan metabolism in the
kynurenine (Kyn) pathway [10]. Growing evidence
suggests that IDO-mediated tryptophan metabolism in
antigen presenting cells and tumor cells represent a vital
mechanism for potential T cell suppression during
tumor growth. Localized tryptophan deficiency and the
accumulation of toxic metabolites in tumor-draining
lymph nodes and the tumor microenvironment could
contribute to the growth arrest, inactivation, and even
death of T cells [11-13]. IDO has been investigated in
cervical, colorectal, hepatocellular, ovarian carcinoma,
endometrial cancer and thyroid cancer [14-18], but to
our knowledge, no detailed studies have investigated the
expression of IDO in NPC.
We therefore aimed to examine the roles of IFNg and
I D Oi nN P C ,i no r d e rt ot h r o wn e wl i g h to nt h e
mechanism by which immune evasion affects therapeu-
tic treatment of NPC.
Methods
Cell culture
The human nasopharyngeal carcinoma cell line CNE2
was established at Hunan Medical College, China
[19,20]. CNE2 cells used in this study were maintained
in our laboratory in RPMI 1640 medium (Gibco-BRL,
MD) supplemented with 10% fetal calf serum (FCS, PAA
Laboratories, MA) and antibiotics (100 U/ml penicillin,
100 g/ml streptomycin). When the monolayer of CNE2
cells reached 60% confluency, IFNg (China National
Biotec Group, Shanghai, China) was added to the
medium at 0-500 U/ml, for the indicated time.
Human peripheral blood was donated by healthy
volunteers, following appropriate informed consent.
Peripheral blood mononuclear cells (PBMCs) were
isolated by density gradient centrifugation through
Ficoll-Hypaque (Tian Jin Hao Yang Biological Manufac-
ture Co., TianJin, China) according to standard proce-
dures. Monocytes and phagocytes were removed by
adherence to plastic by culturing PBMCs in RPMI 1640
containing 50 U/ml exogenous interleukin-2 (IL-2,
Kexing Biotech Co., Shenzhen, China) for 4-5 h. The
non-adherent peripheral blood lymphocyte (PBL)
fraction was harvested and cultured at a density of
2×1 0
6 cells/ml in 24-well plates with complete RPMI
1640 medium (containing 10% FCS, 100 U/ml peni-
cillin and 100 g/ml streptomycin). IL-2 100 U/ml was
added to the medium every other day, for an incubation
period of at least 4 days.
Conditioned medium treatment
CNE2 cells were cultured in 6-well plates (3 × 10
5 cells/
well) in the absence or presence of 50 U/ml IFNg for
12 h, and the medium was then replaced by fresh
medium, with or without 100 M 1-methyl-D/L-trypto-
phan (1 MT, Sigma-Aldrich, MO). Twenty-four hours
after medium replacement, culture medium was har-
vested as conditioned medium (CM) from CNE2 cells
(CNE2-CM), and used for the incubation of PBLs.
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cells, IL-2-treated PBLs were suspended in complete
RPMI 1640 medium or CNE2-CM, and all media were
supplemented with 100 U/ml IL-2. After culture for 24 h,
PBLs were harvested for cytotoxicity assays and the
supernatant was collected and used for incubating CNE2
cells. CNE2 cells were first cultured in complete RPMI
1640 medium for 18 h, and the medium was then
replaced by the above PBL CM and the CNE2 cells were
incubated for 24 h.
Immunohistochemical assay
Formalin-fixed and paraffin-embedded NPC samples
(n = 9) were selected from archival material from the
Department of Pathology in Sun Yat-sen University of
Medical Sciences. The sections were deparaffinized in
xylene and rehydrated through graded alcohol washes to
distilled water. Endogenous peroxidase was blocked with
0.3% H2O2 for 30 min and non-specific staining was
prevented by incubation in commercial goat serum
(Wuhan Boster Biological Technology Ltd, Wuhan,
China). Sections were stained using the streptavidin-
peroxidase (SP) staining method by incubation with
rabbit anti-human IDO polyclonal antibody (1:500,
generated in our laboratory [21]) at room temperature
for 1 h. After washing in phosphate buffered saline (PBS)
containing 0.05% Tween-20 (PBS-T), the sections were
incubated with secondary antibodies from the EnVision™
Detection Kit (Gene Tech, Shanghai, China). Slides were
stained in the absence of primary antibodies to evaluate
non-specific secondary antibody reactions and were
counterstained with hematoxylin.
In order to detect the expression of IDO in CNE2 cells
they were immunohistochemically stained using the
same SP staining method as for the clinical specimens.
Western blot analysis
The treated CNE2 cells were lysed in cell lysis buffer
(50 mmol/l Tris-Cl, pH = 8.0; 150 mmol/l NaCl; 0.02%
NaN3; 0.1% sodium dodecyl sulfate (SDS); 1% NP-40;
0.5% sodium deoxycholate; 1 mol/l EDTA). The lysates
were cleared by centrifugation and denatured by boiling in
Laemmli buffer. Equal amounts of protein (20 g/well)
were separated by 10% SDS-polyacrylamide gel electro-
phoresis and transferred to polyvinylidene difluoride
membranes (Bio-Rad, CA). After blocking in Tris-buffered
saline containing 0.1% Tween-20 and 5% nonfat milk, the
membrane was incubated with the rabbit anti-human IDO
polyclonal antibody, followed by incubation of horse-
radish peroxidase-conjugated anti-rabbit IgG (Wuhan
Boster Biological Technology Ltd). Protein was visualized
by enhanced chemiluminescence (ECL, Pierce, IL), For the
loading control, b-actin (1:10,000, Beijing Biosynthesis
Biotechnology Co., Beijing, China) was probed with the
primary antibodies after the membrane was stripped of the
IDO antibodies using stripping buffer.
Measurement of IDO activity
The culture medium for IDO activity analysis was mixed
with 1/4 volume of 30% trichloroacetic acid and then
centrifuged at maximum speed for 20 min at 4°C to
precipitate the protein. The concentration of Kyn in the
culture medium was measured by reverse phase high-
performance liquid chromatography (HPLC), using a
Waters Alliance HPLC system (Waters, MA). Kyn was
detected by the UV detector at 340 nm and the results
were processed in Breeze version 3.30 SPA. IDO activity
was determined by the specific Kyn production after
subtracting the non-specific Kyn concentration in the
RPMI 1640 medium with 10% FCS.
Flow cytometric analysis
PBLs untreated and pre-treated with IL-2 were plated
into 24-well plates in complete RPMI 1640 medium, or
CNE2-CM without 1 MT (described in 2.2). After 48 h
incubation, cells were harvested, washed with PBS, and
resuspended in annexin V-binding buffer. Fluorescein
isothiocyanate-conjugated annexin V (Trevigen, MD)
was added to a final concentration of 100 ng/ml and
cells were incubated in the dark for 15 min at room
temperature. Propidium iodide (PI, Trevigen) was added
to each sample so that the final concentration of PI was
50 mg/ml before flow cytometric analysis.
Cytotoxicity assay
The cytotoxic activity of the PBLs was determined by
standard 4 h lactate dehydrogenase (LDH) release assay
using CytoTox 96® Non-Radioactive Cytotoxicity Assay
(Promega, WI) in U-bottomed 96-well microplates. To
obtain the target cells, CNE2 cells were seeded at a density of
5×1 0
3 cells/well in U-bottomed 96-well microplates,
cultured for 18 h, and the medium was then replaced by 50
l fresh phenol red-free RPMI 1640 medium (Gibco-BRL)
containing 5% FCS. To prepare the pre-treated effector cells,
IL-2-stimulated PBLs were incubated for 24 h in CNE2-CM
and then collected and resuspended in phenol red-freeRPMI
1640containing5%FCS.Fiftymicrolitersofthesuspensions
were added to each well at various indicated effector:target
(E:T) ratios. After 4 h incubation, the plates were centrifuged
and 50 l of the supernatant was transferred to new 96-well
flat-bottomed plates, following the manufacturer’s instruc-
tions. The release of LDH into the supernatant was
quantified by recording the absorbance at 490 nm. The
percentage of cytotoxicity was calculated as follows:
%(  Cytotoxicity Experimental Effector Spontaneous Target S =− − p pontaneous Target 
                              Maximum
)/(
− −× Target Spontaneous) % 100
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T h ee x p r e s s i o no fI D Oi nt h eN P Cc e l ll i n eC N E 2i sh i g h l y
sensitive to IFNg stimulation
We investigated the effect of IFNg, a well-known potent
IDO inducer, on the IDO expression in the NPC cell line
CNE2. As shown in Fig. 1A and 1B, immunohistochemical
assay identified IDO expression in the cytoplasm of CNE2
cells treated with IFNg, whereas no IDO expression was
found in untreated CNE2 cells. We performed western blot
analysis to investigate the effects of varying concentrations
and incubation periods of IFNg on the expression of IDO
in CNE2 cells. As shown in Fig. 1C, treatment with low
dose IFNg (5 U/ml) induced IDO expression, which was
further increased in an IFNg concentration-dependent
manner. When CNE2 cells were treated with 50 U/ml
IFNg, expression of IDO was observed within 8 h, peaked
at 24 h, and then remained unchanged for at least 72 h
(Fig.1D).TheseresultssuggestthatIDOexpressioninNPC
cells was an inducible event that was highly sensitive to
IFNg stimulation.
Figure 1
Effect of IFNg on indoleamine 2,3-dioxygenase (IDO) expression in the nasopharyngeal carcinoma cell line,
CNE2. (A) and (B) IFNg-induced IDO protein expression in CNE2 cells assessed by immunohistochemistry.
CNE2 cells were treated with (A) or without (B) 50 U/ml IFNg f o r2 4h ,a n ds t a i n e dw i t ha n t i - I D Oa n t i b o d y .T h ei m a g e sw e r e
captured at ×100 magnification, and ×400 magnification for inserts. (C) and (D) IFNg induced IDO protein expression in CNE2
cells in a dose- and time-dependent manner. CNE2 cells were cultured in the presence of indicated concentrations of IFNg for
24 h (C), CNE2 cells were cultured with 50 U/ml IFNg for the indicated incubation time (D). Cells were harvested and IDO
expression was analyzed by western blotting using anti-IDO antibodies. Data are representative of three individual
experiments.
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stimulation in the NPC cell line CNE2
Some recent studies have demonstrated a discrepancy
between IDO expression and its enzymatic activity
[22,23], and we therefore investigated the enzymatic
activity of IDO in NPC cells. Kyn production was
measured as an indicator of IDO activity [24] in CNE2
cells at varying concentrations and incubation periods of
IFNg, using reverse phase-HPLC. CNE2 cells were first
treated with different concentrations of IFNg for 24 h.
Kyn production was undetectable in the culture medium
of untreated cells, but was significantly increased by IFNg
treatment in a dose-dependent manner (Fig. 2A). CNE2
cells were then treated with 50 U/ml of IFNg for 0-72 h
and Kyn production was increased in a time-dependent
manner, after treatment for 24 h (Fig. 2B), whereas basal
levels were maintained in the untreated cells. The HPLC
results indicated that the enzymatic activity of IDO in
CNE2 cells treated with IFNg was enhanced in a dose-
and time-dependent manner.
Activated PBLs induce expression of IDO in the
NPC cell lineCNE2
Since TILs at tumor sites in NPC patients appear to be in
an activated state [25] and may be involved in inducing
IDO expression, we mimicked the interplay between
activated lymphocytes and tumor cells by culturing CNE2
cells in CM from IL-2 stimulated PBLs, and analyzed the
amount of IDO expression by western blot analysis. In
order to establish if IL-2 was able to directly induce the
expression of IDO, CNE2 cells were incubated in
complete culture medium supplemented with 100 U/ml
IL-2 for 24 h. Western blot analysis demonstrated that IL-
2 in the culture medium failed to induce IDO expression
in CNE2 cells (Fig. 3A). To investigate the effect of
activated lymphocytes on IDO expression, CM from PBLs
stimulated by IL-2 was harvested and used to incubate
CNE2 cells. IDO expression was observed in CNE2 cells
after incubation with CM from PBLs for 24 h (Fig. 3B).
IDO expression in NPC cells would alter the microenvir-
onment by depletion of tryptophan and production of
Kyn, so potentially affecting the ability of PBLs to induce
IDO expression. To explore this possibility, PBLs were
stimulated with 100 U/ml IL-2 for 96 h and washed to
remove early generated cytokines. After further incubation
with IL-2-supplemented CNE2-CM from CNE2 cells
treated or untreated with IFNg for 24 h, the PBL
supernatants were collected and used to incubate CNE2
cells for 24 h. Western blot analysis showed that, as with
CM prepared by incubating PBLs with CNE2-CM derived
from untreated CNE2 cells, CM from PBLs which had been
cultured in CNE2-CM derived from IFNg-treated CNE2
cells was also able to induce IDO expression (Fig. 3C).
Exposure to the microenvironment created by
IDO-positive CNE2 cells does not
severely reduce PBL survival
Several reports have suggested that T cells are highly
susceptible to cell death in an IDO-expressing micro-
environment [26,27], and we therefore determined if
exposure to CM from IFNg-treated CNE2 cells reduced
PBL survival. PBLs were pre-treated with or without IL-2
f o r9 6ha n dt h e nc u l t u r e di nC N E 2 - C Md e r i v e df r o m
IFNg-treated or untreated CNE2 cells for 48 h. Cell death
was detected by flow cytometric analysis, using annexin
V and PI as indicators. As shown in Fig. 4, in the IL-2-
untreated groups, PBLs unexposed to CNE2-CM, which
Figure 2
IFNg induced indoleamine 2,3-dioxygenase activity in
CNE2 cells in a dose- and time-dependent manner.
(A) After CNE2 cells were cultured in the presence of
different concentrations of IFNg for 24 h, the supernatants of
CNE2 cells were analyzed for Kyn production using high
performance liquid chromatography (HPLC). (B) CNE2 cells
were cultured with 50 U/ml IFNg for different incubation
times and the supernatants were analyzed for Kyn
production by HPLC. □: untreated groups; ■: treated groups.
Each value is the mean ± SD of three determinations.
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(page number not for citation purposes)served as the control, showed a basal rate of cell death of
1.4 ± 0.3%, and that rate was unaffected by exposure to
CNE2-CM derived from IFNg-treated or untreated CNE2
cells. A similar result was observed in the IL-2-treated
groups, where the death rate of PBLs exposed to CNE2-
CM derived from IFNg-treated or untreated CNE2 was
t h es a m ea st h a to ft h ec o n t r o l .
Exposure to conditioned medium derived from
IDO-positive CNE2 cells impairs cytolytic
activity of PBLs
Although TILs were often present in NPC specimens,
they showed no evidence of anti-tumor activity at the
tumor site, suggesting inhibition by the tumor tissue
microenvironment. We used an in vitro assay to see if the
cytolytic activity of lymphocytes was impaired by the
tumor milieu created by expression of IDO. A standard
LDH release assay was conducted using CNE2 cells as
targets and PBLs stimulated by IL-2 for 96 h as effectors.
PBLs lysed the target cells after IL-2 treatment, but the
lysis rate was remarkably reduced by exposure to CNE2-
CM from IFNg-treated CNE2 cells (Fig. 5A). To further
demonstrate the effect of IDO on the impaired cytotoxi-
city of PBLs, the specific IDO inhibitor, 1 MT, was used
to block enzyme activity. Activated PBLs were cultured in
CNE2-CM from CNE2 cells treated with or without
50 U/mL IFNg and/or 100 M 1 MT for 24 h, and the
cytolytic activity was evaluated. The cytolytic activity of
PBLs against CNE2 cells was functionally restored by the
addition of 1 MT, compared with the groups cultured in
the absence of 1 MT (Fig. 5B). HPLC analysis demon-
strated that the addition of 100 M 1 MT dramatically
reduced Kyn production (Fig. 5C).
We also investigated if PBL cytotoxicity could be restored
when IDO was removed. Activated PBLs were incubated
with CNE2-CM derived from IFNg-treated or untreated
CNE2 cells containing 100 U/mL IL-2 for 96 h, and
restored groups were then transferred to fresh medium
containing 100 U/mL IL-2 and incubated for 24 h. The
cytolytic activity of each group was analyzed by LDH
release assay. PBLs cultured in CNE2-CM from IFNg-treated
CNE2 cells exhibited decreased cytolytic activity against
target cells, compared with those in CNE2-CM from
untreated CNE2 cells (Fig. 5D). However, the cytolytic
activity of PBLs cultured in CNE2-CM derived from IFNg-
treated CNE2 cells was fully restored when the CNE2-CM
was replaced by fresh medium for 24 h. In the presence of
100 M 1 MT, both un-restored and restored groups
maintained a similar level of cytolytic activity. These results
suggest that the tumor milieu created by IDO-positive NPC
cells could significantly impair the cytolytic function of
activated lymphocytes, providing a potential mechanism
for immune evasion in patients with NPC.
Figure 3
Western blotting analysis to detect indoleamine 2,3-
dioxygenase (IDO) expression in the nasopharyngeal
carcinoma cell line CNE2 induced by activated
peripheral blood lymphocytes (PBLs). (A) CNE2 cells
were treated with or without 100 U/ml IL-2 or 50 U/ml IFNg
for 24 h. (B) PBLs were stimulated with 100 U/ml IL-2 for 96
h, washed to remove early generated cytokines and cultured
in fresh complete RPMI 1640 medium supplemented with
100 U/ml IL-2 for 24 h. The PBL supernatant was then used
as the CM to incubate CNE2 cells for 24 h. (C) PBLs were
stimulated with 100 U/ml IL-2 for 96 h and washed to
remove early generated cytokines. After further incubation
with IL-2-supplemented CNE2-CM from CNE2 cells treated
or untreated with IFNg for 24 h, the PBL supernatants were
collected and used to incubate CNE2 cells for 24 h.
Expression of IDO in CNE2 cells was detected by western
blotting analysis with anti-IDO antibodies. The data are
representative of three individual experiments. CM,
conditioned medium; CNE2-CM, conditioned medium
derived from CNE2 cells.
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patients with NPC
In order to attain clinical evidence of IDO expression in
NPC, the immunohistochemical assay was performed in
NPC specimens and sections of normal nasopharyngeal
tissues. The NPC specimens were stratified into three
types according to WHO histological classification. No
IDO-positive staining was observed among the epithelial
cells or keratinizing cells in the sections of normal
nasopharyngeal tissues (Fig. 6A) or NPC type I (Fig. 6B),
whereas IDO-positive cells with typical nuclei were seen
scattered in the sections of NPC type II (Fig. 6C) and III
(Fig. 6D). In addition, infiltration of lymphocytes into
the tumor tissues could be clearly identified in NPC type
II and III, judged by morphology, consistent with the
previously reported characteristics of NPC [25].
Discussion
Unlike most carcinomas in which TILs are infrequently
observed, NPC has intense lymphocyte infiltration in the
tumor tissue [25,28], though these infiltrated lympho-
cytes apparently have limited ability to eliminate the
tumor. The present study demonstrated, for the first
time, that expression of IDO occurred in the NPC-
derived cell line CNE2 and in tumor tissues from
patients with NPC. Furthermore, we have shown that
the expression of IDO in CNE2 cells was inducible by
activated PBLs and that the cytolytic function of PBLs
was impaired in the tumor milieu created by enzyme
activity of IDO, providing a novel insight into the role of
IDO in tumor immune evasion in NPC.
The infiltration of lymphocytes to tumor sites suggests that
an immune response has been initiated, and Tang et al
found that TILs in undifferentiated NPC are in an activated
state [29]. However, NPC still progresses in most patients,
and the prognosis of advanced stage NPC is frustratingly
poor[30],indicatingthattumorimmuneevasionoccursin
these patients. Several mechanisms have been proposed to
explain this e.g., the abnormal expression of IL-10 and
Figure 4
Exposure to the conditioned medium derived from indoleamine 2,3-dioxygenase (IDO)-positive CNE2 cells did
not induce PBL death. PBLs were pre-treated with or without IL-2 for 96 h and then cultured in CNE2-CM derived from
IFNg-treated or untreated CNE2 cells for a further 48 h. Cell death was detected by flow cytometric analysis, using annexin V
and propidium iodide as indicators. CNE2-CM, conditioned medium derived from CNE2 cells.
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IFNgsecretionandperforinexpressioninCD8
+Tcells[33].
In this study, we found that the immunosuppressive
enzyme IDO was highly expressed in tumor tissues from
NPC patients, suggesting that IDO-mediated immunosup-
pression may be involved in immune evasion, and so
contribute to NPC progression.
Previous studies have demonstrated posttranslational
control of IDO, implying that IDO expression and
activity may not be correlated [34,35]. However, in the
present study, analysis of Kyn production proved that
the IDO expressed in CNE2 cells possessed functional
enzymatic activity, and suggesting that active IDO was
induced in NPC cells by IFNg.W ea l s os h o w e dt h a tI F N g
induced IDO expression in CNE2 cells at concentrations
as low as 5 U/ml, implying that IDO expression in NPC
cells could be easily induced by low levels of IFNg.T h e
time course of IDO expression in CNE2 cells treated with
IFNg indicated that, once IDO protein was synthesized, it
Figure 5
Cytolytic activity of peripheral blood lymphocytes (PBLs) was impaired by incubation with CNE2-CM from
indoleamine 2,3-dioxygenase-positive CNE2 cells. (A) Activated PBLs were cultured with CNE2-CM from CNE2 cells
treated with or without 50 U/ml IFNg for 24 h and cytolytic activity against CNE2 cells was evaluated using a standard lactate
dehydrogenase (LDH) release assay, as described in Materials and Methods. The effector:target (E/T) ratios are indicated. (B)
Activated PBLs were cultured with CNE2-CM from CNE2 cells treated with or without 50 U/ml IFNg and/or 100 M1M Tf o r
24 h, and cytolytic activity was evaluated using the LDH release assay. The E/T ratio was 10:1. (C) CNE2 cells were treated
with or without 50 U/ml IFNg and/or 100 M 1 MT for 24 h. The CNE2 cell supernatants were analyzed for kynurenine
production by high performance liquid chromatography, as described in Materials and Methods. (D) Activated PBLs were
incubated with CNE2-CM from IFNg-treated or untreated CNE2 cells containing 100 U/ml IL-2 for 96 h, and restored groups
were transferred to IL-2-supplemented fresh medium for 24 h, the cytolytic activity of each group was analyzed by LDH
release assay. The E/T ratio was 10:1. Effector cells, activated PBLs; target cells, CNE2 cells; CNE2-CM, conditioned medium
from CNE2 cells; Kyn, kynurenine.
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lasting effect of IDO in NPC patients, resulting in severe
tryptophan deprivation and Kyn accumulation at tumor
sites. Hence, dense infiltration of lymphocytes or
systemic administration of IFNg could induce IDO
expression and cause persistent, enhanced IDO activity
in NPC patients.
Western blot analysis demonstrated that CM from
activated PBLs was able to induce IDO expression in
CNE2 cells. PBLs are known to functionally express
multiple inflammatory cytokines, including IFNg and
TNFa, which are believed to be potent inducers of
enzyme expression [36]. The ability of PBLs to induce
IDO expression was also observed after culture in CNE2-
CM derived from IDO-expressing CNE2 cells, suggesting
that the IDO-generating condition did not directly
impair cytokine release. This is in agreement with the
results of previous studies, which found that the T cell
activation markers, including IL-2, IFNg, CD69, CD25,
and CD71, were still expressed under conditions
depleted of tryptophan and/or enriched in Kyn [13,37].
Figure 6
Expression of indoleamine 2,3-dioxygenase (IDO) in nasopharyngeal carcinoma.N o r m a ln a s o p h a r y n g e a lt i s s u e( A ) ,
tumor section from NPC type I (B), type II (C) and type III (D) were stained with antibodies to IDO, as described in Materials
and Methods. Images were captured at ×100 magnification, and ×400 magnification for inserts.
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(page number not for citation purposes)It has also been reported that merely activating the
immune system, such as by adoptive T cell transfer using
a conventional lymphoblastoid cell line-reactivated
preparation [38,39], or by vaccination with dendritic
cells [40,41], might be inadequate for immunotherapy,
and may result in up-regulation of IFNg and/or TNFa
production, leading to IDO expression in tumor cells
[41]. Further studies are needed to determine if IDO
expression in CNE2 cells is directly induced by these
cytokines, if these cytokines act synergistically to increase
the expression of IDO, or if there is an independent
pathway of IDO expression that exists in the CM from
activated PBLs.
In the present study, we found that IFNg-induced IDO
expression in CNE2 cells did not promote apoptotic
death of PBLs. IDO-expressing cells have been reported
to promote apoptosis of blood T cells due to the
cytotoxicity of tryptophan metabolites, such as Kyn,
but not through tryptophan deficiency. Terness et al. and
Frumento et al. showed that Kyn concentrations > 100
M suppressed T cell proliferation by inducing cell
death, whereas concentrations < 30 M did not cause T
cell apoptosis [26,42]. In the current study, IDO-
expressing CNE2 cells generated Kyn in an IFNg dose-
dependent manner, and Kyn concentration in the cell
culture system did not exceed 10 M after treatment with
50 U/ml of IFNg,w h i c hw a st o ol o wt op r o m o t eTc e l l
death. Although it is difficult to extrapolate from in vitro
to in vivo situations, the lack of a cytotoxic effect due to
the presence of Kyn at a low concentration in the tumor
microenvironment could explain previous observations
of high densities of lymphocytes in NPC tumor tissue.
Once expressed in the tumor cells, IDO creates a local
environment depleted of tryptophan and enriched in
Kyn, thus rendering TILs susceptible to proliferation
arrest and/or dysfunction. In our in vitro study, we found
that exposure to CNE2-CM derived from IDO-expressing
CNE2 cells dramatically weakened the cytolytic function
of PBLs against target cells, but this attenuation could be
reversed by addition of the IDO inhibitor, 1 MT. In this
case, the down-regulation of the cytolytic function of
PBLs did not appear to be due to the production of viral
IL-10 (vIL-10), which was frequently observed in NPC
tumor tissue [43], because vIL-10 was not detectable in
CNE2 cells by reverse transcription polymerase chain
reaction analysis (data not shown). These results suggest
that PBLs are susceptible to the IDO-generating environ-
ment and that blocking IDO activity could restore their
anti-tumor activity. We demonstrated that the cytolytic
activity of PBLs could be fully restored by the replace-
ment of CM from IDO-expressing CNE2 cells with fresh
medium. Previous studies also found that IDO-mediated
T cell proliferation arrest was overcome by the addition
of tryptophan and removal of metabolites from the
medium [9,26,42]. These observations suggest that the
IDO-mediated suppression of PBL cytotoxicity is a
reversible event, and that blocking IDO activity in
t u m o rc e l l sc o u l dh e l pt or e - establish the anti-tumor
immune response, especially in tumors with high
densities of infiltrating lymphocytes, such as NPC.
Conclusion
In conclusion, we identified IDO expression in NPC and
found that the enzyme could be efficiently induced by
low dose IFNg in the NPC cell line CNE2. PBLs exposed
to the milieu generated by IDO-expressing CNE2 lost
their cytolytic function, but did not undergo promoted
cell death. We suggest that the negative effect of IDO
e x p r e s s i o ni nN P Cc e l l so nt h ec y t o l y t i cf u n c t i o no fP B L s
could contribute to the lack of efficacy of current
immunotherapeutic strategies. Blocking both two iso-
forms of IDO, IDO1 and IDO2, by using their inhibitors
L- and/or D-1-methyl-tryptophan [44] may provide a
potential means of improving the outcomes of immu-
notherapy for the treatment of NPC.
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